Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2

Salivary IgAs and Their Role in Mucosal Neutralization of SARS-CoV-2 Variants of Concern

“…Potential limitations of our study might be the combined evaluation of BNT162b2 and mRNA-1273 vaccine recipients as well as the sampling day after last immunization. However, our findings on salivary immunity support the idea of an adapted vaccine or alternative delivery strategy such as mucosal vaccine administration as a booster for optimal protection against SARS-CoV-2 ( 3 , 8 ).…”

Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines

“…However, the development of updated vaccines as boosters is needed for better protection against immune escape of current subvariants (especially BA.4 and BA.5) and possible future epidemic subvariants. 5 …”

A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core

“…Therefore, more than 4 mice in each group are sufficient to meet the requirement of statistical power. To reduce the error and improve the reliability of the results, we generally used 6-10 mice per group following the previous studies 38 , 39 , 40 and the suggestions of in vivo experiments. 41 6-10 mice per group had sufficient statistical power for making a valid test according to the sample size calculation described by Charan and Kantharia.…”